top of page

Investor Disclosure

Prospectus

Regulated by the British Columbia Securities Commission, Canada, since June 2025. 

SEDAR +

Secure web-based system used by all Canadian regulated corporations for full disclosure. - Financial statements, news releases, shareholder meetings and voting and all corporate action disclosures.

Common shares           64,745,192
Warrants                          52,942,303
Options                            0
Preference  shares      non

Share Capitalisation

Valuation Report PureFlowCath

Valuation Future Royalty US$31 M
       Revenue per year following                 FDA approval 
 

Patent Awards PureFlowCath

PureFlowCath Catheter medical device received EU award, the first major award to Fowley Catheter since 1928.

Board of Management

Robert Rhodes          Director/CEO

Terrence Larkan        Chairman/CFO

Dr Marshall Walker  Non Exec Director

David Toyoda             Non Exec Director

Billy Williams.             Non Exec Director

bottom of page